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prolonged protection against pathogenic 
SIV challenge in monkeys immunized with 
SIV DNA delivered by employing rhesus 
CMV and Adenoviral vectors correlated 
with high frequencies of virus-specific 
effector memory CD4+ T cell responses 
within the potential sites of SIV replica-
tion (Hansen et al., 2011). In our lab, studies 
testing peptide-based vaccine (Nehete et al., 
1998, 2001, 2005, 2008) and adenovirus vec-
tored vaccines (Mercier et al., 2007; Weaver 
et al., 2009) against systemic or mucosal 
challenge with different strains of simian 
human immunodeficiency viruses (SHIV 
ku2, SHIV89p, and SHIV 162p3), revealed 
strong correlation for virus control, to 
undetectable levels in significant population 
of animals, preferentially with antigen spe-
cific cellular immune responses (CD4+ and 
CD8+ T cells). We also assessed functional 
characteristics of memory T cells subsets as 
potential prognostic markers for changing 
viral loads and/or disease progression using 
the SHIV-infected rhesus macaque model 
and observed that functional impairment of 
CD4+ T cells in general, and of central mem-
ory subset in particular, may be a potential 
indicator/predictor of chronic infection 
with immune dysfunction, which could be 
assayed relatively easily using non-specific 
PMA + I stimulation (He et al., 2011).
Two other immune cell types recognized 
for potential contributions to influence virus 
control in SIV infected rhesus macaques 
and HIV-infected humans include CD4+ T 
cells subsets that either produce IL-17, Th17 
cells, or exert immunosuppressive function, 
CD25+FoxP3+ regulatory T cells or T-reg 
(Cecchinato and Franchini, 2010). Depletion 
of Th17 cells in humans as well as macaques, 
relatively soon after virus exposure, has been 
associated with the dissemination of micro-
bial products from the infected gut, thereby 
adding to the systemic immune activation and 
disease progression. On the other hand, T-regs 
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Rhesus macaques infected with simian 
immunodeficiency virus (SIV) represent 
the most widely used model for studies 
related to understanding infection, pathol-
ogy, immunology, and intervention strate-
gies for HIV infection and AIDS in humans. 
This model recapitulates the significant 
impact of host immunogenetics and inter-
individual variations on the natural disease 
course of HIV-AIDS in humans. In addi-
tion to the parallel kinetics for fast- and 
slow-progressing disease course observed 
in majority of animals, a small subset of 
animals exhibit long-term non-progres-
sion (LTNP) or elite control (EC) status 
defined as low to undetectable viral loads 
in the absence of any interventions for 
prolonged periods. Therefore, the rhesus 
macaque model has been and continues to 
be the most extensively adopted experimen-
tal system for studies to not only confirm 
observations from HIV-ADIS in humans 
but also to validate several mechanistic fea-
tures of the infection and disease course, 
which otherwise would be impractical and 
immoral to be performed in humans.
The natural EC of HIV-1 in humans and 
of SIV in rhesus macaques has been attrib-
uted to the contributions of variety of host 
and viral factors (Betts et al., 2006; Saksena 
et al., 2007; Freel et al., 2010). Virus-specific 
CD4+ T helper cells are central for maintain-
ing effective immunity in case of a number 
of chronic viral infections including HIV, 
where infected individuals that control 
viremia in the absence of antiviral therapy 
exhibit persistent and vigorous HIV-specific 
CD4+ T cell responses, in particular to the 
viral core protein p24 that display poly-
functionality in terms of secreting multi-
ple cytokines and chemokines (Kalams and 
Walker, 1998). Employing the SIV-rhesus 
model, Louis Picker’s group showed that 
strong and early containment in terms of 
undetectable plasma viral loads as well as 
have been associated with  compromised anti-
viral T cell responses. Substantive studies in 
the non-human primates combined with epi-
demiological observations in humans suggest 
that both these cells subsets, through influenc-
ing innate and adaptive immune responses, 
significantly impact the inflammatory milieu 
of the host to ultimately affect the outcome of 
the immunodeficiency virus infection (Favre 
et al., 2009; Dandekar et al., 2010; Kanwar 
et al., 2010).
Clinically healthy HIV-infected indi-
viduals that maintain stable high CD4+ T 
cell counts also exhibit strong and early 
onset of anti-HIV CD8+ T cell responses 
pointing to their protective role, which 
prompted elegant experiments that tested 
in vivo CD8+ T cell depletion in SIV infected 
rhesus macaques demonstrating the critical 
role of these immune cells in the early con-
trol of infection (Deeks and Walker, 2007; 
Freel et al., 2010). While the role of CD4+ 
T cells in cell-mediated immunity is mani-
fested in terms of production of a variety of 
cytokines, CD8+ T cells are more frequently 
recognized for their cytolytic property even 
though they are capable of multiple func-
tions that include production of a variety of 
cytokines and soluble factors to restrict viral 
replication in infected cells (Buchbinder 
et al., 2008). In this regard, Watkins group 
(Goulder and Watkins, 2004) using in vitro 
assays based on cytokine production by the 
CD8+ T cells demonstrated suppression of 
viral replication and also showed that CD8+ 
T cell clones, from monkeys in the elite SIV 
control group, recognizing the same epitope 
differ significantly in their capacity to sup-
press SIV replication. These studies further 
demonstrated that the in vitro efficacy of the 
CD8+ T cells to suppress virus replication is 
not necessarily tied always to production 
of cytokine most commonly assayed, such 
as IFN-γ, TNG-α, or IL-2 (Goulder and 
Watkins, 2004).
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The power of non-human primates as 
the experimental animal models of choice 
for HIV-AIDS, specifically to understand 
the non-progression of infection/disease, 
extends beyond the rhesus macaques. The 
sooty mangabeys and African green mon-
keys are two non-human primate species 
that are the natural hosts for SIV infection 
where the virus exhibits high replication 
capacity with transient or severe CD4+ T 
cells loss but without clinical signs of sim-
ian AIDS. Valuable information has been 
gathered from studies in these models for 
SIV infection and the potential of host and 
viral factors to serve as correlates of pro-
tection and/or EC. In sooty mangabeys 
CD3+CD4−CD8− T cells (double-negative 
T cells) capable of producing Th1, Th2, and 
Th17 cytokines seem to partially compen-
sate for the loss of CD4+ T cell function in 
maintaining disease-free status exemplified 
by controlled viral replication and low levels 
of immune activation (Milush et al., 2011). 
These studies bring to focus the importance 
of double-negative T cells and studies to 
better understand their modulation in 
HIV-AIDS (Silvestri et al., 2005; Barry et al., 
2007). Similarly, studies in African green 
monkeys emphasize the lack of chronic 
T cell activation as a critical determinant 
for the difference between the non-patho-
genic SIV in this model and the pathogenic 
HIV-1/SIV infections in humans and rhesus 
macaques. Accordingly, this is an active area 
of research pursued by several groups focus-
ing on the innate immune system and the 
induction of immunosuppressive media-
tors, specifically during early SIV infection 
(Kornfeld et al., 2005; Jacquelin et al., 2009).
ConClusion
Non-progression to disease in HIV-infected 
individuals is a rare but highly important 
observation for designing informed and 
logical strategies for controlling and even 
preventing HIV-AIDS. Studies in the non-
human primate models thus far revealed 
parallels for all stages of HIV disease pro-
gression in humans including that rare 
non-progression. Important lessons learned 
from these models included identification, 
with certainty, of contributing host immu-
nological and genetic factors in more practi-
cal terms. Most significant among these are 
the demonstration of the relevance of CD8+ 
T cells in controlling infection and the prac-
tical implications of protective MHC alleles, 
high degree of sequence homology for the 
Mamu-B*08-restricted epitopes from SIV 
to match the HIV peptide-binding motifs 
for HLA-B*2705 in humans, despite sub-
stantial sequence differences between these 
MHC alleles. Further detailed studies of the 
Mamu-B*08 peptide-binding motif ena-
bled this group to identify six additional 
novel Mamu-B*08-restricted SIV-specific 
CD8+T cell immune responses directed 
against epitopes in Gag, Vpr, and Env. This 
remarkable similarity of peptide-binding 
motifs of MHC alleles in two different 
species highlight not only the important 
role for the specific peptides and related 
immune responses, but also the relevance 
of macaques expressing such unique MHC 
alleles as model to examine EC of immu-
nodeficiency virus replication.
One of the HIV encoded genes, nef, has 
long been recognized to be important for 
viral infectivity, though it was shown to be 
not required for in vitro viral replication 
in cell cultures. Clinical epidemiological 
studies identified HIV-infected asymp-
tomatic individuals to harbor virus with 
mutated nef gene sequences, specifically 
point mutations involving the cysteine 
residue at position 138 (Cys-138), over 
a sustained period of 3 years of infec-
tion without any disease progression 
(Premkumar et al., 1996). Incidentally, this 
Cys-138 mutation in the nef gene was also 
identified in the chimpanzee immunode-
ficiency virus (CIV), another member of 
the lentivirus family with close similarity 
to HIV, but chimpanzees infected with this 
virus do not progress to AIDS (Premkumar 
et al., 1996). Furthermore, SIVagm, an SIV 
variant that commonly inhabits African 
Green monkeys expresses nef gene with 
multiple cysteine residues including the 
Cys-138 mutation, does not cause AIDS 
in this monkey (Premkumar et al., 1996). 
These observations were confirmed by 
experimental evidence from studies 
employing the SIV-rhesus model, notably 
by the Desrosier’s group (Kestier et al., 
1991) who showed that SIV variants with 
nef gene deletions, but not wild type SIV, 
failed to maintain high viral loads neces-
sary to cause AIDS in infected adult rhesus 
monkeys (Kestier et al., 1991). Based on 
these reports, several studies explored the 
attenuated SIV strains with deletion of the 
nef gene alone or along with additional 
viral genes as potential candidate vaccines.
The unique strength of the virus-
specific CD8+ T cell immunity for virus 
control in LTNP and EC has been most 
widely elaborated in the literature to be 
associated with host genetic factors, spe-
cifically expression of certain class I major 
histocompatibility complex (MHC-1) 
alleles (Migueles et al., 2000; Fellay et al., 
2009). It has been well recognized that 
individuals expressing HLA-B27- and 
-B57 alleles are among the elite control-
lers of HIV replication, implying that 
CD8+ T cell responses restricted by these 
host genes exert potent anti-HIV effects. 
Analogous to these observations are stud-
ies in the SIV-rhesus model demonstrat-
ing that animals expressing Mamu-A*001 
and Mamu-B*08 exhibit low to undetect-
able viral loads without experimental 
interventions, so much so that 50% of 
Mamu-B*08-positive rhesus macaques of 
Indian origin were shown to effectively 
control SIVmac239 replication to become 
EC (Loffredo et al., 2008). Such parallels 
between human and rhesus MHC alleles 
contributing for virus control, defined as 
significantly lower set-point viral load 
and prolonged survival time, were noted 
specifically for HLA-B*14, and -B*57 in 
humans and Mamu-A*001, A*002, A*008, 
A*011; B*001, B*003, B*004, B*008, B*017, 
B*029, DRB*w201, DRB1*0401/06/11, 
and DPB1*06 in macaques (Goulder and 
Watkins, 2008). The most compelling evi-
dence, beyond the genetic linkage stud-
ies, for the contribution of host immune 
responses restricted by specific MHC 
alleles is presented in recent studies from 
the Watkin’s group (Mudd et al., 2012). In 
this study, Mamu-B*08 expressing rhesus 
macaques when vaccinated with three pep-
tide sequences restricted by Mamu-B*08 
generated high frequencies of correspond-
ing CD8+ T cell response in blood, lymph 
nodes, and colon that was associated with 
efficient viral control. Furthermore, in two 
of the eight animals from the study viral 
rebounds during the chronic infection 
phase correlated with the emergence of 
escape variants mutated specifically in all 
three epitope sequences, demonstrating a 
direct role for CD8+ T cells in viral control.
The most powerful recognition for the 
strength of the SIV-rhesus model for HIV-
AIDS research comes from studies by the 
Sette group (Sette et al., 2005) that ana-
lyzed a panel of ∼900 peptides to show a 
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